The James Whale Fund for Kidney Cancer changed its name to Kidney Cancer UK on 7 February 2016 to become the UK's leading specialist kidney cancer charity. http://www.kcuk.org.uk/ It seeks to help reduce the harm caused by kidney cancer by increasing knowledge and awareness, providing patient information, and by supporting research into the causes, prevention and treatment of the disease. The charity was founded in 2006 by the broadcaster James Whale whose experience of dealing with the disease in 2000, when he lost a kidney in the process, spurred him on to set up a charity to help others in a similar position. The Fund depends primarily on voluntary donations and in its short history has published a definitive guide to kidney cancer, set up a Patient Support Network and Careline, established an online renal nurse training programme and campaigned for access to life extending drugs for NHS kidney cancer patients. The charity is governed by a board of Trustees and has its head office in Cambridge, UK. [1]
The aims of the charity are stated as being
James Whale Fund for Kidney Cancer is committed to raising awareness of kidney cancer amongst a range of audiences including the general public, GPs, clinicians, policy makers, health authorities and the media.
The fund is involved in the lobbying of government for increased awareness, and access to new drugs not currently available on the NHS.
In 2012, The fund announced that it had established a relationship with TrialReach to provide information to patients about clinical trials [3]
The James Whale Fund for Kidney Cancer represents the needs of kidney cancer patients in the political arena by lobbying government to;
The Fund attends the meetings of the All Party Parliamentary Group on Cancer at Westminster to keep abreast of government directives for the care and management of cancer patients in the UK. In addition, the Fund lobbies Westminster, the Welsh Assembly and the Scottish Parliament for access to drugs and to increase awareness of the disease.
The Fund is involved with all technology appraisals for new kidney cancer drugs conducted by the National Institute for Health and Clinical Excellence (NICE). The Fund provides expert input to the technology appraisals through the provision of expert patient witnesses on the technology appraisal committees and through appeals against NICE reimbursement decisions for kidney cancer drugs on the NHS.
Finally, the Fund lobbies MPs and Lords on behalf of kidney cancer patients to increase awareness and knowledge of the disease within government, and on specific issues with respect to patient access to drugs.
James Whale fund is also working with a number of corporates and engaging in cause-related marketing.
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health and Social Care in England that publishes guidelines in four areas:
The Leukemia & Lymphoma Society (LLS), a 501(c)(3) charitable organization founded in 1949, is the largest voluntary health organization dedicated to fighting blood cancer in the world. The LLS's mission is to cure leukemia, lymphoma, Hodgkin's lymphoma and myeloma, and improve the quality of life of patients and their families.
The Brain Tumour Charity is a UK-based, Charity Commission registered, charity dedicated to funding research, raising awareness of brain tumours, reducing diagnosis times and providing support and information for people with brain tumours, their families and friends.
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM), smoldering myeloma, and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone. It is taken by mouth.
Sorafenib, is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
HIV/AIDS was first diagnosed in 1981. As of year-end 2018, 160,493 people have been diagnosed with HIV in the United Kingdom and an estimated 7,500 people are living undiagnosed with HIV. New diagnoses are highest in gay/bisexual men, with an estimated 51% of new diagnosis reporting male same-sex sexual activity as the probable route of infection. Between 2009 and 2018 there was a 32% reduction in new HIV diagnosis, attributed by Public Health England (PHE) to better surveillance and education. PHE has described an "outbreak" in Glasgow amongst people who inject drugs, and has campaigns targeting men who have sex with men in London and other major cities. London was the first city in the world to reach the World Health Organization target for HIV, set at 90% of those with HIV diagnosed, 90% of those diagnosed on HAART and 90% of those on HAART undetectable. The UK as a whole later achieved the same target. Under the Equality Act 2010, it is illegal to discriminate against someone based on their HIV status in the UK.
The National Health Service (NHS) is the umbrella term for the publicly funded healthcare systems of the United Kingdom (UK). Since 1948, they have been funded out of general taxation. There are three systems which are referred to using the "NHS" name. Health and Social Care in Northern Ireland was created separately and is often locally referred to as "the NHS". The four systems were established in 1948 as part of major social reforms following the Second World War. The founding principles were that services should be comprehensive, universal and free at the point of delivery—a health service based on clinical need, not ability to pay. Each service provides a comprehensive range of health services, free at the point of use for people ordinarily resident in the United Kingdom apart from dental treatment and optical care. In England, NHS patients have to pay prescription charges; some, such as those aged over 60 and certain state benefit recipients, are exempt.
The INCTR Challenge Fund is the UK charity raising funds for projects co-ordinated by the International Network for Cancer Treatment Research (INCTR) that improve the care delivered to cancer patients in developing countries and help reduce their suffering.
The Royal Osteoporosis Society (ROS), formerly the National Osteoporosis Society, established in 1986, is the only UK-wide charity dedicated to improving the prevention, diagnosis and treatment of osteoporosis. It is based in Camerton, Somerset, England.
TB Alert is a charity working to raise awareness about and support effective treatment of the disease tuberculosis in the UK and internationally. It was registered in 1998 and launched on World Tuberculosis Day in 1999 in response to the resurgence of tuberculosis (TB) in the UK and worldwide. It is headquartered in Brighton.
The National Institute for Health Research (NIHR) is a United Kingdom government agency which funds research into health and social care. With a budget of over £1.2 billion in 2019–20, its mission is to "improve the health and wealth of the nation through research". The NIHR was established in 2006 under the government's Best Research for Best Health strategy, and is funded by the Department of Health and Social Care. As a research funder and research partner of the NHS, public health and social care, the NIHR complements the work of the Medical Research Council. NIHR focuses on the all aspects of the research process, from translating laboratory findings to clinical research to applying the discoveries in health and social care.
Biomedical sciences are a set of sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology that are of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. In explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science.
The Pancreatic Cancer Action Network (PanCAN) is a United States-based 501(c)(3) charity that funds research, provides patient/caregiver support, conducts community outreach and advocates for increased federal research funding for those affected by pancreatic cancer.
The Cancer Drugs Fund (CDF) was introduced in England in 2011. It was established in order to provide a means by which National Health Service (NHS) patients in England could get cancer drugs rejected by National Institute for Health and Care Excellence because they were not cost effective. Its establishment was confirmed by the UK government's coalition agreement in 2010, and by the White Paper, Equity and excellence – Liberating the NHS.
The Edinburgh Cancer Research Centre (ECRC), also known as the Cancer Research UK Edinburgh Centre and the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.
The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that is sequencing whole genomes from National Health Service patients. The project is focusing on rare diseases, some common types of cancer, and infectious diseases. Participants give consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment and care of diseases.
Kidney Cancer UK is a British charity established in 2000 to support "kidney cancer patients, their carers, medical professionals and scientific researchers."
The Urology Foundation (TUF), is a charity that works across the UK and Ireland with the aim of improving the knowledge and skills of surgeons who operate on diseases of the male and female urinary-tract system and the male reproductive organs and funds research to improve outcomes of all urological conditions and urological cancers.
{{cite web}}
: CS1 maint: archived copy as title (link)